Navigation Links
U.S. Patent and Trademark Office Issues Mylan's Specialty Division, Dey L.P., Three Additional Patents Protecting Perforomist(R) Inhalation Solution
Date:1/12/2009

PITTSBURGH, Jan. 12 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Dey L.P. has been issued several additional U.S. patents protecting the company's Perforomist(R) Inhalation Solution, a chronic obstructive pulmonary disease (COPD) treatment.

U.S. Patent No. 7,462,645 was issued Dec. 9, 2008, and is directed to treatment through the administration of a ready-to-use, storage stable composition of formoterol. This patent covers Dey's Perforomist(R) Solution, and its term extends until June 22, 2021. The patent will be listed in the "Orange Book," giving Dey four Orange Book-listed patents covering Perforomist Solution.

U.S. Patent Nos. 7,465,756 and 7,473,710 were issued Dec. 16, 2008, and Jan. 6, 2009, respectively. These patents are directed to compositions of "R-formoterol," a specific form of the formoterol molecule, and their use.

In addition, Dey has received a "Notice of Allowance" on yet another patent also directed to the use of R-formoterol. This patent is expected to issue shortly. Upon its issuance, Dey will possess seven patents directed to compositions of formoterol, R-formoterol and/or their uses.

Mylan's Vice Chairman and CEO Robert J. Coury stated: "We are very pleased with the recent issuance of these additional patents, which we believe only further bolster Dey's already strong intellectual property portfolio, and we will continue to aggressively protect and assert Dey's IP rights. Dey is currently pursuing a patent infringement lawsuit against Sepracor relating to its Brovana(R) product."

Dey also has additional pending U.S. patent applications directed to formoterol-containing compositions and their use in the treatment of respiratory conditions.

Mylan Inc., which provides products to customers in mo
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
2. URMC, Lighthouse Biosciences Awarded U.S. Patent for Diagnostic Technology
3. URMC, Lighthouse Biosciences awarded US patent for diagnostic technology
4. Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company License to Certain Alzheimers Patents and Patent Applications
5. Procter & Gamble Reaches Settlement on Patent Infringement Lawsuit
6. SpectraScience Awarded U.S. Patent 7,469,160 for Its Unique Methods and Apparatus for Evaluating Image Focus
7. Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute
8. FreePatentsOnline Launches the CitePatents Program : Making it Easy for Bloggers and Journalists to Reference Patents, and Add Patent Search to Websites
9. HPS Files Patent for Mood-Enhancing Compound Naturally Found in Sea Coral
10. Kidnapped senior needed IU-patented home security system
11. Enigma Diagnostics Announces a Signed Term Sheet for Patent Licenses with Roche Molecular Systems, Inc.

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...Call/-HardtoTreatDiseases(HTDS; http://www.htdsmed...,isprovidingthisbriefupdatetoitsfollowersandshareh...Ustemcellcompanyandmergerdiscussions.Thisrelatesto...companymade. http://www.pinksheets.com/pink/quote/...caBiochemarealsodiscussingonexpandingtheresearchto...
(Date:11/24/2009)...TheAmericanDentalAssociation(ADA)hassignedanagreem...aspartofapilotprogramtoimprovetheoralhealthinunder...oordinator(CDHC)isamemberofthedentalhealthteamwhow...dentalcaretoimprovetheiroralhealth. ,, TheCDHCp...--includingscreeningsandfluoridetreatments.However...
(Date:11/24/2009)...Thereisanewgameintownwhenitcomestodealingwithalcoh...ealisticstrategieswheretraditionalapproachestoalco...roupcalledHAMS--HarmReduction,AlcoholAbstinenceand...portandinformationalgroupforpeoplewhodrinkalcohol....lismtellsusthatonly7%ofpeoplewithanalcoholprobleme...
(Date:11/24/2009)...N,LA,ME,NE,NDandSD ,, ALEXANDRIA,Va.,Nov.24/PR...onSaturdaytotakeupthehealthcarereformlegislation,t...mpaigntargetingSenatorsinninestates-Alaska,Arkansa...kota,andSouthDakota. ,, The$2.0millionadbuyhigh...reportwhichconfirmscutstoMedicareofhalfatrilliondo...
(Date:11/24/2009)...LifeInsuranceCompanyofAmerica(Guardian),oneofthela...eebenefitsforsmallandmid-sizedcompanies,todayannou...surancecoverageguidelinesformammographyscreenings....ocietyandAmericanMedicalAssociation(AMA)recommenda....S.PreventiveServicesTaskForcerecommendedincreasin...
Breaking Medicine News(10 mins):Health News:Hard To Treat Diseases (HTDS) Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank Targeted Merger 2Health News:Hard To Treat Diseases (HTDS) Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank Targeted Merger 3Health News:ADA Launches Community Dental Health Coordinator Pilot Program at Temple University 2Health News:Harm Reduction for Alcohol: An Idea Whose Time Has Arrived 2Health News:Senate Votes to Proceed - 60 Plus Announces New 9 State TV Campaign Targeted at Senators to Protect Medicare 2Health News:Senate Votes to Proceed - 60 Plus Announces New 9 State TV Campaign Targeted at Senators to Protect Medicare 3
...egarding the outbreak of the deadly Rift valley Fe...warned against consumption of raw milk. // ...en borderline areas, is safe from the viral livest...due to hygienic concerns but also due to the fact ...
...linois at Chicago study published in the January i...ority of fertility clinic Web sites does not adher...nes. The study also found that services offer... offer financial incentives. Many consumers re...
...ts that doctors should advise and persuade patient...heir partners and bring// them for check up and tr...g kits or drugs in order to help reduce infection ...ransmitted infections often makes this difficult. ...
...ency, Pharmac, is in the process of doing away wit... Pharmac intends to phase out the ‘Aropax’ brand ... ‘Loxamine’. It is estimated that Aropax is used b...e, except for the appearance and the packaging. Fu...
...ake Forest University Baptist Medical Center are h...lving 83 other sites that will test 3,000 patients... is good for heart failure patients. Though d...he group of patients who primarily have heart fail...
... we shed tears. But exactly what our tears are mad... A new study sheds some light on the complex desig...call tear film, which is made up of three distinct...layer of fatty, oily substances collectively calle...
Other Medicine News:Health News:Experts Warn Against Raw Milk Following Rift Valley Fever Outbreak in Kenya 2Health News:Experts Warn Against Raw Milk Following Rift Valley Fever Outbreak in Kenya 3Health News:Fertility Clinic Web Sites Doesn’t Adhere to Ad-Guideline 2Health News:New International Study to Test Exercise in Heart Failure Patients 2Health News:New International Study to Test Exercise in Heart Failure Patients 3Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 2Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 3
(Date:11/24/2009)...,, RALEIGH,N.C.,Nov.24/PRNewswire/--Pharmace...ingsolutionsforthepharmaceuticalandbiotechindustry...italMarketplace .Thenew HospitalMarketplace e-cour...Excellence(TM) series,acomprehensiveseriesofe-cour...dmanagedmarketsknowledgeforcommercialprofessionals...
(Date:11/24/2009)...,, HOLMDEL,N.J.,Nov.24/PRNewswire/--SpartaSy...leaderinenterprisequalityandcompliancesolutions,to...ingconsumerproductcompanyandtheparentcompanyforglo...ivewithTrackWiseEnterpriseQualityManagementSystem(...oharmonizeandstreamlinequalityoperationsthatinclud...
(Date:11/24/2009)...,, SALTLAKECITY,Nov.24/PRNewswire/-- Infinit...thelaunchofanewonlinevisiontherapyprogrameyeQ,thes...n-officetherapymethods. ,, eyeQ wasintroduceda...ustrypresidentelect,Dr.BradHabermehlbelievesthe ey...yLearningCenterinFlintMichigan.Itallowshispatients...
Breaking Medicine Technology:Pharmaceutical Institute Launches New Training Resource Focused on the Hospital Marketplace 2SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 2SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 3Infinite Mind Announces the Launch of a New Online Vision Therapy Program eyeQ 2At the fungal farmers market only the best cyanobacteria are for sale 9661 1At the fungal farmers market only the best cyanobacteria are for sale 9661 2Nick Jonas to Speak on Juvenile Diabetes at National Press Club August 24 55055 1Nick Jonas to Speak on Juvenile Diabetes at National Press Club August 24 55055 2Cell Therapeutics Inc Announces Closing of Registered Offering of 2430 Million of Preferred Stock and Warrants 13648 1Cell Therapeutics Inc Announces Closing of Registered Offering of 2430 Million of Preferred Stock and Warrants 13648 2
...lood pressure reductions of 30.8 mm Hg,systolic bl...pressure (DBP),at five weeks and 21.1/19.3 mm Hg (... of patients with severe hypertension, AVAL...4.6 mm Hg (SBP/DBP), at 8 weeks, and 22.1/11.6 mm...ectively for irbesartan and HCTZ alone, in a study...
...Proprietary siRNA Molecule in Acute .... 19 Quark Pharmaceuticals, Inc., a,development-s... and,developing novel RNA interference-based thera...temic dosing in humans of its proprietary product,... developed by Quark for,the treatment of Acute Ren...
Other Medicine Technology:Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 2Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 3Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 4Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 5Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 6Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 7Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 2Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 3Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 4
Glucose UV Liquidplus
Glucose Color Liquidplus Reagent
Glucose (Oxidase)
Glucose (Hexokinase)
Medicine Products: